Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH

Despite the emergence of high quality randomized trial data with the use of antithrombotic agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in patients with coronavirus disease 2019 (COVID‐19), questions still remain as to optimal patient selection for these st...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of thrombosis and haemostasis Ročník 20; číslo 10; s. 2226 - 2236
Hlavní autoři:	Spyropoulos, Alex C., Connors, Jean M., Douketis, James D., Goldin, Mark, Hunt, Beverley J., Kotila, Taiwo R., Lopes, Renato D., Schulman, Sam, the International Society on Thrombosis and Haemostasis
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Inc 01.10.2022 Elsevier Limited John Wiley and Sons Inc
Témata:	anticoagulant Anticoagulants - therapeutic use antiplatelet Antiplatelet therapy antithrombotic therapy coronavirus disease 2019 Coronaviruses COVID-19 COVID-19 Drug Treatment Critical care Fibrinolytic Agents - therapeutic use Hemostasis hospitalization Humans Patients Platelet Aggregation Inhibitors - therapeutic use Recommendations and Guidelines severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis Thrombosis - drug therapy Thrombosis - prevention & control Venous Thromboembolism - prevention & control anticoagulant antithrombotic therapy hospitalization severe acute respiratory syndrome coronavirus 2 antiplatelet coronavirus disease 2019
ISSN:	1538-7836, 1538-7933, 1538-7836
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!